comprehensive -WSS

comprehensive

author：fashion 2025-09-06 10:59:17 - browse：3

President of Bayer U.S. Sebastian Guth speaks with STAT reporters at STAT's Boston headquarters, March 13, 2024 — Bayer's U.S. president, Sebastian Guth, emphasized at an interview at the STAT offices in Boston that the pharma company is no longer just focused on small molecules. Alissa Ambrose/STAT

German pharmaceutical company Bayer is expanding its U.S. pharma business significantly, despite corporate turmoil and pricing pressures that have led many in the drug industry to bemoan the potential end of the American biotech innovation boom.

Bayer’s C-suite has been on a soul-searching mission for the last year, spurred by new leadership and the realization that the company is, as new CEO Bill Anderson said earlier this month, “badly broken.”

The biggest fissure is the debt and litigation costs stemming from Bayers’s 2018 acquisition of agriculture firm Monsanto, but the aspirin-maker’s pharmaceutical portfolio is also facing strain. Some of Bayer’s top products, including the anticoagulant drug Xarelto and the eye medication Eylea, are under patent pressure. Xarelto is also one of the first drugs to be subject to Medicare price negotiations under the Inflation Reduction Act, though Johnson & Johnson owns U.S. rights to the drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： How to make the FDA’s new prescription one

explore

WSS

Gene therapy has helped boys walk. Can scientists keep it that way?

New Covid vaccine is recommended for everyone 6 months or older

Walmart eyes Medicare Advantage provider ChenMed

Long Covid needs a new name — and a new frame

Private equity could exacerbate cardiology's overuse problem, experts fear

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

entertainment

comprehensive

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

WATCH: Why do fingernails fall off when they're damaged?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

IRA could hurt research into orphan drugs for rare diseases

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA proposes changes to key medical devices approval pathway

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

White House touts steps to stem shortages of cancer treatments

Walensky prepares to leave CDC — and Congress — behind

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

knowledge

Cloning humans is technically possible. It's curious no one has tried

STAT's guide to the next generation of CAR

What would happen to your eyes if you looked at the solar eclipse?

Will the IRA bring competition to the biologics market?

Walmart eyes Medicare Advantage provider ChenMed

Why we need to separate burnout from moral injury in health care

explore

explore

explore

leisure time